A woman treated with cyclophosphamide (Cytoxan) may develop an embryopathy. Other women will have an apparently normal pregnancy.
Some women receiving cyclophosphamide may suffer miscarriage during the pregnancy.
Risk factors for embryopathy may include:
(1) exposure in first trimester
(2) high dose
General features:
(1) growth retardation
(2) developmental delay
Facial dysmorphism may include
(1) microbrachycephaly (small head with flattening of occipital area)
(2) craniosynostosis
(3) hypotelorism
(4) shallow orbits with proptosis
(5) blepharophimosis (eyelids underdeveloped and cannot open fully)
(6) small misshapen ears
(7) preauricular pits
(8) broad, flat nasal bridge
(9) microstomia
(10) high-arched palate
(11) micrognathia
Skeletal anomalies may include:
(1) hypoplastic thumb
(2) oligodactyly
